



image

1646

PATENT/Docket No.: 6322.N

Serial No.: 10/076,708

Page No. 1

CERTIFICATE OF MAILING (37 CFR 1.8)

Date of Deposit with U.S. Postal Service: March 3, 2004

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail under 37 CFR 1.8 on the date indicated above and is addressed to Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450

JULIE K LYONS

Name of Person Mailing Paper

Julie K Lyons
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1646
Examiner : Olga N. Chernyshev
Applicant(s) : SK Sharma, KB Rank
Serial No. : 10/076,708
Filed : February 15, 2002
For : ASSAYS FOR ASSESSING A β -TAU AGGREGATION

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT TRANSMITTAL
UNDER 37 CFR 1.97 AND 1.98

Sir:

Information Disclosed. The information disclosed consists of the following:

[X] **Form PL-1449.** Provided herewith are copies of patent(s) and/or publication(s) as listed in the attached form PL-1449.

[X] At least to the extent required under §1.98(a)(3), a concise explanation of the relevance of references listed in form PL-1449 is:

- [] contained in the above-captioned specification as filed;
- [] provided in a communication enclosed with this paper;
- [X] provided in the International Search Report enclosed with this paper; and/or
- [] not necessary as all of the references cited are in the English language.

- ☐ **Disclosure from Predecessor Application.** Provided herewith is a copy (or the copy is already present in the present file wrapper in accordance with §1.53(d)) of one or more forms PL-1449 and/or search/examination reports of record in this or a predecessor application, Serial No. filed , the benefit of which is claimed under 35 USC 120. Copies of references are present in the prosecution history of the referenced application and are not supplied herewith pursuant to §1.98(d).

Basis for Consideration. This information disclosure statement is entitled to consideration by the Office under:


- ☐ **§1.97(b)**, as being filed within three months of the filing date of the above-captioned application and/or the date of entry of the National Stage, if later, and/or before the mailing date of the first Office action on the merits. Applicant(s) is/are unaware that any office action has issued in this case. However, in the event a first office action has issued, prior to the mailing of this document, then authorization is given to charge the late fee to the deposit account identified below.
- ☐ **§1.97(c)**, as being filed after the period specified in §1.97(b), but before the mailing date of a final action under §1.113 and/or the notice of allowance under §1.311.
Consideration of this information disclosure statement at this time is requested for the reason checked below:
- ☐ **Authorization is hereby provided to charge Deposit Account No. 21-0718 the fee set forth in §1.17(p), \$180.00, or such greater or lesser amount as the Commissioner may from time to time prescribe by rule. Triplicate copies of this paper are provided to facilitate the charge to the Deposit Account.**
- ☐ A statement as specified in 37 CFR 1.97(e) below.
- ☐ **§1.97(d)**, as being filed after the period specified in §1.97(c), but on or before payment of the issue fee and is accompanied by:
- ☐ **Authorization to charge Deposit Account No. 21-0718 the fee set forth in §1.17(i), \$130.00, or such greater or lesser amount as the Commissioner may from time to time prescribe by rule. Triplicate copies of this paper are provided to facilitate the charge to the Deposit Account.**
- ☐ A petition requesting consideration of the information disclosure statement; and
- ☐ A statement as specified in 37 CFR 1.97 (e) below.
- ☒ **§1.97(e)**, this is a **supplemental information disclosure statement**. A prior information disclosure statement has already been filed. Applicant certifies, as provided in 37 CFR 1.97 (e), that



- ☒ Each new item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.
- ☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing below, after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three (3) months prior to the filing of this statement.

Disclaimer. In accordance with §1.97(g) and (h), the filing of this information disclosure statement is not to be construed as an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56, and is not to be construed as a representation that a search has been made.

Respectfully submitted,


Edward F. Rehberg, Attorney
Registration No. 34,703

Date: 3-3-04

Pharmacia & Upjohn Company
Global Intellectual Property
301 Henrietta Street
Kalamazoo, Michigan 49001

Telephone No. (269) 833-7829 or (269) 833-9500
Telefax No. (269) 833-8897 or (269) 833-2316

Attachment(s)

- ☒ Form 1449 with copies of reference(s)
☐ Form 1449 from predecessor application (no references)
☐ Communication providing concise explanation of relevance
☒ International Search Report



PTO/SB/08b (06-03)

Approved for use through 06/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number

10/076,708

Filing Date

February 15, 2002

First Named Inventor

Satish K. Sharma

Art Unit

1646

Examiner Name

Chernyshev, Olga N

Attorney Docket Number

6322.N

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	GOETZ, J ET AL: "Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta42 fibrils" Science, American Association for the Advancement of Science, US, vol. 293, no. 5534, pages 1491-1495, 2001.	
	2	GOURAS GUNNAR K ET AL: "Intraneuronal Abeta 42 accumulation in human brain" American Journal of Pathology, vol. 156, no. 1, pages 15-20, January 2000.	
	3	HARDY JOHN ET AL: "Genetic dissection of Alzheimer's disease and related demetias: Amyloid and its relationship to tau" Nature Neuroscience, vol. 1, no. 5, pages 355-358, 1998.	
	4	LEWIS J ET AL: "Enhanced neurofibrillary degeneration in transgenic mice expressin mutant tau and APP" Science, American Association for the Advancement of Science, vol. 293, no. 5534, pages 1487-1491, 2001.	
	5	RANK KB ET AL: "Direct interaction of soluble human recombinant tau protein with Abeta 1-42 results in tau aggregation and hperphosphorylation by tau protein kinase II" Febs Letters, Elsevier Science Publishers, Amsterdam, NL, vol. 514, no. 2-3, pages 263-268, 2002.	
	6	TAKASHIMA A ET AL: "Amyloid beta peptide (25-35) induces tau phosphorylation and decrease microtubule-forming ability in rat hippocampal culture" Abstracts of the Society for Neuroscience, Society for Neuroscience, Wahshington, DC US, vo. 21, no. 1-3, page 1719,	
	7	TOMIDOKORO YASUSHI ET AL: "Abeta amyloidosis induces the initial stage of tau accumulation in APPSW mice" Neuroscience Letters, vol. 299, no. 3, pages 169-172, 2001.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.